On Friday, Shares of Keryx Biopharmaceuticals (NASDAQ:KERX), dropped -1.73%, to $9.67.
Keryx Biopharmaceuticals, declared that two national insurance providers have added Auryxia(TM) to their Medicare Part D formularies. Auryxia is the first and only absorbable, iron-based phosphate binder for the treatment of elevated serum phosphorus levels in people with chronic kidney disease on dialysis. Together, these new formularies will enhance unrestricted access to Auryxia, across Medicare Part D and commercial insurance providers, to about 65 percent of people in the U.S. presently taking phosphate binders.
“The inclusion of Auryxia on these major insurance providers’ Part D formularies, which we expect will start processing claims in the third quarter, significantly expands unrestricted access to Auryxia for people on dialysis and their caregivers,” said Greg Madison, Chief Executive Officer of Keryx Biopharmaceuticals. “We are progressing nicely towards our aim of broad, unrestricted access to about 80 percent of phosphate binder prescriptions, across both Medicare Part D and commercial insurance providers, within 12 months post-approval. Looking ahead, we are focused on ongoing to raise awareness of Auryxia’s clinical profile among the prescribing community and ensuring that the vast majority of dialysis patients have access to this important medicine.”
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia.
Shares of Maxim Integrated Products Inc. (NASDAQ:MXIM), climbed 0.17%, to $34.56.
Maxim Integrated Products, will declare fiscal fourth quarter 2015 results after market close on Thursday, July 23, 2015.
A conference call and live webcast will follow at 2:00 p.m. Pacific Time, which can be accessed at www.maximintegrated.com/company/investor. To listen via telephone, dial (866) 804-3547 (toll free) or (703) 639-1328.
Maxim Integrated Products, Inc. designs, develops, manufactures, and markets various linear and mixed-signal integrated circuits worldwide. The company also provides a range of high-frequency process technologies and capabilities for use in custom designs.
Shares of UBS Group AG (USA) (NYSE:UBS), during its Friday’s trading session raised 1.58% to $21.87.
The UBS Global Asset Administration US Pension Fund Fitness Tracker saw the funding ratio of the typical corporate US pension plan rise to about 87% in the second quarter of 2015. We recalibrated our model plan further to the adoption of new mortality tables at the last fiscal year-end.
“The introduction of the new mortality tables had the net effect of reducing the funding ratio by about six percentage points. Factoring in the strong decrease in liabilities, the average funding ratio rebounded in the second quarter, increasing on average by about one percentage point. It is worth noting that in the absence of the mortality adjustment, the average funding ratio would stand close to 92%, the same level it was in the last quarter of 2013. Interest rates reversed their decline with the yield on the long end of the Treasury market increasing 58 basis points over the second quarter. We continue to advise our clients to adhere to their de-risking program as the timing/direction of movements in long-term interest rates is uncertain,” said Robert Guzman, head of Pension Risk Administration at UBS Global Asset Administration.
UBS Group AG, together with its auxiliaries, provides wealth administration, retail and corporate, asset administration, and investment banking products and services worldwide.
Finally, Laboratory Corp. of America Holdings (NYSE:LH) , lost -1.18% $120.75.
Laboratory Corp. of America Holdings, declared that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.
The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee (Trustee) and the conversion agent.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. The company offers a range of clinical laboratory tests and procedures, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, STD tests, HCV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
